Summary
PCVX Chart
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason
The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.
Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity
Vaxcyte, Inc.'s positive results achieved from phase 2 dose-finding study using VAX-24 for the prevention of invasive pneumococcal disease in infants; Further post 4 dose data expected 2nd of 2025. It is expected that the 7 major pneumococcal disease markets are to reach a value of $11.6 billion by 2035. VAX-24 goes beyond that of Prevnar 20 in terms of targeting 4 more serotypes than it.
Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine
Vaxcyte Inc. PCVX on Monday released topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Pfizer Inc's PFE Prevnar 20 (PCV20) in healthy infants.
Vaxcyte, Inc. Dividends
Vaxcyte, Inc. Earnings
| 12 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
| 5 Aug 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
| 5 Aug 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
| 6 May 2025 Date | | - Cons. EPS | - EPS |
| 25 Feb 2025 Date | | - Cons. EPS | - EPS |
| 12 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
| 5 Aug 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
| 5 Aug 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
| 6 May 2025 Date | | - Cons. EPS | - EPS |
| 25 Feb 2025 Date | | - Cons. EPS | - EPS |
Vaxcyte, Inc. (PCVX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Vaxcyte, Inc. ever had a stock split?
Vaxcyte, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Grant E. Pickering CEO | NASDAQ (NGS) Exchange | 92243G108 Cusip |
| US Country | 414 Employees | - Last Dividend | - Last Split | 12 Jun 2020 IPO Date |
Overview
Vaxcyte, Inc. represents a pioneering force in the field of biotechnology, focusing its considerable expertise on the development of innovative protein vaccines aimed at the prevention and treatment of bacterial infectious diseases. Born from its previous incarnation as SutroVax, Inc., the company underwent a rebranding in May 2020 to emerge as Vaxcyte, Inc., marking a new chapter in its commitment to combatting infectious diseases. Since its establishment in 2013, Vaxcyte has dedicated itself to advancing science and technology with its headquarters located in San Carlos, California. The company's approach blends cutting-edge research with clinical acumen, underscoring its ambition to address some of the most challenging bacterial pathogens through its vaccine development pipeline.
Products and Services
- VAX-24:
As Vaxcyte, Inc.'s frontrunner candidate, VAX-24 is a 24-valent investigational pneumococcal conjugate vaccine designed with the vision of preventing invasive pneumococcal disease. This vaccine exemplifies the company's dedication to innovation in vaccine technology, targeting a wide range of pneumococcal strains to offer comprehensive protection.
- VAX-31:
VAX-31 is a testament to Vaxcyte’s forward-thinking strategy, aiming to provide immunity against emerging bacterial strains and the ever-growing challenge of antibiotic resistance. This vaccine candidate is designed to extend the protective reach beyond the current vaccine offerings and address future public health needs.
- VAX-A1:
Focusing on the causative agent of severe throat infections, VAX-A1 is a novel conjugate vaccine candidate targeting Group A Streptococcus. VAX-A1 represents Vaxcyte's ambition to prevent diseases caused by this common, yet potentially dangerous, bacterium.
- VAX-PG:
Vaxcyte's innovative approach to oral health is embodied in VAX-PG, a novel protein vaccine candidate aimed at combating the keystone pathogen responsible for periodontitis. This vaccine underlines the company's commitment to expanding the scope of vaccine-preventable diseases to include oral health conditions.
- VAX-GI:
Addressing the need for vaccines against gastrointestinal infections, VAX-GI is being developed to prevent disease caused by Shigella, a bacterium responsible for significant illness globally. This vaccine candidate highlights Vaxcyte's efforts to tackle a broad spectrum of infectious agents through its diversified vaccine pipeline.
Contact Information
